InflaRx shares surge 30.08% after-hours on positive Phase 2a INF904 data for HS and CSU.

InflaRx surged 30.08% in after-hours trading following the release of positive Phase 2a clinical trial data for its oral C5aR inhibitor INF904 in treating hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). The trial demonstrated rapid and clinically meaningful reductions in inflammatory lesions, pain scores, and urticaria activity, with no serious adverse events reported. Efficacy metrics, including HiSCR50 responses in HS and UAS7 reductions in CSU, exceeded historical placebo benchmarks and compared favorably to approved therapies. The company highlighted INF904’s potential as a “pipeline-in-a-product” with a projected $1 billion addressable market and plans to initiate a Phase 2b trial in HS by 2026. The data, presented in a webcast and supported by strong safety results, fueled investor optimism about INF904’s development trajectory and commercial potential.